(TECH) Bio-Techne - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 6.956m USD | Total Return: -5.1% in 12m

Reagents, Antibodies, Immunoassays, Analytical Instruments, Diagnostic Kits
Total Rating 39
Safety 76
Buy Signal -0.63
Biotechnology
Industry Rotation: -12.2
Market Cap: 6.96B
Avg Turnover: 153M
Risk 3d forecast
Volatility44.1%
VaR 5th Pctl7.36%
VaR vs Median1.37%
Reward TTM
Sharpe Ratio0.02
Rel. Str. IBD12.7
Rel. Str. Peer Group29.3
Character TTM
Beta1.167
Beta Downside1.743
Hurst Exponent0.510
Drawdowns 3y
Max DD50.91%
CAGR/Max DD-0.33
CAGR/Mean DD-0.67
EPS (Earnings per Share) EPS (Earnings per Share) of TECH over the last years for every Quarter: "2021-03": 0.45, "2021-06": 0.47, "2021-09": 0.46, "2021-12": 0.47, "2022-03": 0.54, "2022-06": 0.51, "2022-09": 0.45, "2022-12": 0.47, "2023-03": 0.53, "2023-06": 0.55, "2023-09": 0.41, "2023-12": 0.4, "2024-03": 0.48, "2024-06": 0.49, "2024-09": 0.42, "2024-12": 0.42, "2025-03": 0.56, "2025-06": 0.53, "2025-09": 0.42, "2025-12": 0.46, "2026-03": 0.53,
EPS CAGR: 0.40%
EPS Trend: 9.2%
Last SUE: -0.55
Qual. Beats: 0
Revenue Revenue of TECH over the last years for every Quarter: 2021-03: 243.552, 2021-06: 259.028, 2021-09: 257.719, 2021-12: 269.276, 2022-03: 290.376, 2022-06: 288.228, 2022-09: 269.655, 2022-12: 271.581, 2023-03: 294.146, 2023-06: 301.32, 2023-09: 276.935, 2023-12: 272.598, 2024-03: 303.428, 2024-06: 306.099, 2024-09: 289.458, 2024-12: 297.031, 2025-03: 316.181, 2025-06: 316.964, 2025-09: 286.555, 2025-12: 295.877, 2026-03: 311.415,
Rev. CAGR: 2.96%
Rev. Trend: 95.0%
Last SUE: -0.75
Qual. Beats: 0

Warnings

Below Avwap Earnings

Tailwinds

No distinct edge detected

Description: TECH Bio-Techne

Bio-Techne Corporation develops and manufactures high-quality reagents, instruments, and services for the global life sciences, diagnostics, and bioprocessing markets. Headquartered in Minneapolis, the company operates via two primary segments: Protein Sciences, which focuses on biological reagents and proteomic analytical tools, and Diagnostics and Spatial Biology, which provides molecular diagnostic assays and clinical controls.

The company functions as a key supplier in the Life Sciences Tools & Services sector, a market characterized by high barriers to entry due to the specialized manufacturing requirements for recombinant proteins and antibodies. Bio-Techne utilizes a razor-and-blade business model, where the placement of automated protein analysis instruments drives recurring revenue through the subsequent sale of proprietary consumables and assays.

Investors can evaluate these recurring revenue streams and historical growth trends further on ValueRay.

Headlines to Watch Out For
  • Bioprocessing demand for cell and gene therapy reagents drives protein science revenue
  • Academic and commercial research budget fluctuations impact core reagent and antibody sales
  • Spatial biology adoption and automated proteomic tool scaling expand operating margins
  • Diagnostic assay growth depends on clinical adoption of exosome and tissue-based tests
  • High exposure to Chinese market volatility and biotechnology capital expenditure cycles
Piotroski VR‑10 (Strict) 7.5
Net Income: 109.6m TTM > 0 and > 6% of Revenue
FCF/TA: 0.11 > 0.02 and ΔFCF/TA 2.22 > 1.0
NWC/Revenue: 44.17% < 20% (prev 37.89%; Δ 6.27% < -1%)
CFO/TA 0.12 > 3% & CFO 294.9m > Net Income 109.6m
Net Debt (80.5m) to EBITDA (259.0m): 0.31 < 3
Current Ratio: 4.49 > 1.5 & < 3
Outstanding Shares: last quarter (156.9m) vs 12m ago -1.26% < -2%
Gross Margin: 64.96% > 18% (prev 0.66%; Δ 6.43k% > 0.5%)
Asset Turnover: 46.62% > 50% (prev 45.71%; Δ 0.90% > 0%)
Interest Coverage Ratio: 15.11 > 6 (EBITDA TTM 259.0m / Interest Expense TTM 10.5m)
Altman Z'' 5.69
A: 0.21 (Total Current Assets 688.0m - Total Current Liabilities 153.3m) / Total Assets 2.55b
B: 0.45 (Retained Earnings 1.15b / Total Assets 2.55b)
C: 0.06 (EBIT TTM 158.7m / Avg Total Assets 2.60b)
D: 2.32 (Book Value of Equity 1.08b / Total Liabilities 465.3m)
Altman-Z'' Score: 5.69 = AAA
Beneish M -3.18
DSRI: 0.92 (Receivables 217.9m/237.1m, Revenue 1.21b/1.21b)
GMI: 1.01 (GM 64.96% / 65.75%)
AQI: 0.96 (AQ_t 0.61 / AQ_t-1 0.64)
SGI: 1.00 (Revenue 1.21b / 1.21b)
TATA: -0.07 (NI 109.6m - CFO 294.9m) / TA 2.55b)
Beneish M-Score: -3.18 (Cap -4..+1) = AA
What is the price of TECH shares? As of May 21, 2026, the stock is trading at USD 46.70 with a total of 2,738,656 shares traded.
Over the past week, the price has changed by +4.22%, over one month by -22.77%, over three months by -18.66% and over the past year by -5.14%.
Is TECH a buy, sell or hold? Bio-Techne has received a consensus analysts rating of 4.13. Therefore, it is recommended to buy TECH.
  • StrongBuy: 7
  • Buy: 3
  • Hold: 5
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the TECH price?
Analysts Target Price 61.4 31.5%
Bio-Techne (TECH) - Fundamental Data Overview as of 20 May 2026
P/E Trailing = 63.4714
P/E Forward = 20.7039
P/S = 5.7452
P/B = 3.2511
P/EG = 0.582
Revenue TTM = 1.21b USD
EBIT TTM = 158.7m USD
EBITDA TTM = 259.0m USD
Long Term Debt = 200.0m USD (from longTermDebt, last quarter)
Short Term Debt = 14.2m USD (from shortTermDebt, last quarter)
Debt = 290.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 80.5m USD (from netDebt column, last quarter)
Enterprise Value = 7.04b USD (6.96b + Debt 290.3m - CCE 209.8m)
Interest Coverage Ratio = 15.11 (Ebit TTM 158.7m / Interest Expense TTM 10.5m)
EV/FCF = 26.10x (Enterprise Value 7.04b / FCF TTM 269.6m)
FCF Yield = 3.83% (FCF TTM 269.6m / Enterprise Value 7.04b)
FCF Margin = 22.27% (FCF TTM 269.6m / Revenue TTM 1.21b)
Net Margin = 9.05% (Net Income TTM 109.6m / Revenue TTM 1.21b)
Gross Margin = 64.96% ((Revenue TTM 1.21b - Cost of Revenue TTM 424.3m) / Revenue TTM)
Gross Margin QoQ = 66.88% (prev 64.65%)
Tobins Q-Ratio = 2.76 (Enterprise Value 7.04b / Total Assets 2.55b)
Interest Expense / Debt = 1.11% (Interest Expense 3.22m / Debt 290.3m)
Taxrate = 28.33% (20.2m / 71.2m)
NOPAT = 113.7m (EBIT 158.7m * (1 - 28.33%))
Current Ratio = 4.49 (Total Current Assets 688.0m / Total Current Liabilities 153.3m)
Debt / Equity = 0.14 (Debt 290.3m / totalStockholderEquity, last quarter 2.09b)
Debt / EBITDA = 0.31 (Net Debt 80.5m / EBITDA 259.0m)
Debt / FCF = 0.30 (Net Debt 80.5m / FCF TTM 269.6m)
Total Stockholder Equity = 2.00b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.22% (Net Income 109.6m / Total Assets 2.55b)
RoE = 5.49% (Net Income TTM 109.6m / Total Stockholder Equity 2.00b)
RoCE = 7.23% (EBIT 158.7m / Capital Employed (Equity 2.00b + L.T.Debt 200.0m))
RoIC = 5.01% (NOPAT 113.7m / Invested Capital 2.27b)
WACC = 9.72% (E(6.96b)/V(7.25b) * Re(10.09%) + D(290.3m)/V(7.25b) * Rd(1.11%) * (1-Tc(0.28)))
Discount Rate = 10.09% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -42.22 | Cagr: -0.87%
[DCF] Terminal Value 72.44% ; FCFF base≈250.1m ; Y1≈250.6m ; Y5≈267.1m
[DCF] Fair Price = 22.19 (EV 3.56b - Net Debt 80.5m = Equity 3.47b / Shares 156.6m; r=9.72% [WACC]; 5y FCF grow -0.32% → 3.0% )
EPS Correlation: 9.23 | EPS CAGR: 0.40% | SUE: -0.55 | # QB: 0
Revenue Correlation: 94.98 | Revenue CAGR: 2.96% | SUE: -0.75 | # QB: 0
EPS next Quarter (2026-09-30): EPS=0.44 | Chg30d=-4.36% | Revisions=-64% | Analysts=7
EPS current Year (2026-06-30): EPS=1.92 | Chg30d=-2.74% | Revisions=-75% | GrowthEPS=+0.2% | GrowthRev=-0.9%
EPS next Year (2027-06-30): EPS=2.06 | Chg30d=-4.70% | Revisions=-75% | GrowthEPS=+7.3% | GrowthRev=+4.8%
[Analyst] Revisions Ratio: -75%